Saif M. MM-398 Achieves Primary Endpoint of Overall Survival in Phase III Study in Patients with Gemcitabine Refractory Metastatic Pancreatic Cancer. JOP [Internet]. 27May2014 [cited 8May2024];15(3):278-9. Available from: http://www.serena.unina.it/index.php/jop/article/view/2507